Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
5.72 (1y: -2%)
Market Cap 259.9 M P/E(ttm)
Enterprise Value 191.57 M P/B 2.00
XNPT- NAS (USA)
XenoPort, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$5.72
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt No Debt
XNPT's Cash to Debt is ranked higher than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. XNPT: No Debt )
XNPT' s 10-Year Cash to Debt Range
Min: 8.78   Max: No Debt
Current: No Debt
Equity to Asset 0.819
XNPT's Equity to Asset is ranked higher than
78% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. XNPT: 0.819 )
XNPT' s 10-Year Equity to Asset Range
Min: -1.61   Max: 0.82
Current: 0.82
-1.61
0.82
Interest Coverage No Debt
XNPT's Interest Coverage is ranked higher than
51% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. XNPT: No Debt )
XNPT' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 2.12
M-Score: -5.29
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -143.70
XNPT's Operating margin (%) is ranked lower than
84% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. XNPT: -143.70 )
XNPT' s 10-Year Operating margin (%) Range
Min: -5504.8   Max: 18.3
Current: -143.7
-5504.8
18.3
Net-margin (%) -142.5
XNPT's Net-margin (%) is ranked lower than
84% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. XNPT: -142.5 )
XNPT' s 10-Year Net-margin (%) Range
Min: -4876   Max: 24.8
Current: -142.5
-4876
24.8
ROE (%) -23.7
XNPT's ROE (%) is ranked lower than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. XNPT: -23.7 )
XNPT' s 10-Year ROE (%) Range
Min: -87.8   Max: 22.5
Current: -23.7
-87.8
22.5
ROA (%) -19.4
XNPT's ROA (%) is ranked lower than
68% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. XNPT: -19.4 )
XNPT' s 10-Year ROA (%) Range
Min: -68   Max: 16.3
Current: -19.4
-68
16.3
ROC (Joel Greenblatt) (%) -808.40
XNPT's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. XNPT: -808.40 )
XNPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1905.2   Max: -808.4
Current: -808.4
-1905.2
-808.4
Revenue Growth (%) -17.5
XNPT's Revenue Growth (%) is ranked higher than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. XNPT: -17.5 )
XNPT' s 10-Year Revenue Growth (%) Range
Min: -62.1   Max: 84.4
Current: -17.5
-62.1
84.4
EBITDA Growth (%) -24.8
XNPT's EBITDA Growth (%) is ranked higher than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. XNPT: -24.8 )
XNPT' s 10-Year EBITDA Growth (%) Range
Min: -43.6   Max: -6.8
Current: -24.8
-43.6
-6.8
EPS Growth (%) -23.8
XNPT's EPS Growth (%) is ranked higher than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. XNPT: -23.8 )
XNPT' s 10-Year EPS Growth (%) Range
Min: -42.6   Max: -5.6
Current: -23.8
-42.6
-5.6
ยป XNPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

XNPT Guru Trades in Q2 2012

PRIMECAP Management 125,000 sh (New)
Chuck Royce 102,000 sh (unchged)
Jim Simons 502,900 sh (-12.59%)
» More
Q3 2012

XNPT Guru Trades in Q3 2012

PRIMECAP Management 127,000 sh (+1.6%)
Chuck Royce Sold Out
Jim Simons Sold Out
» More
Q4 2012

XNPT Guru Trades in Q4 2012

PRIMECAP Management 127,000 sh (unchged)
» More
Q1 2013

XNPT Guru Trades in Q1 2013

Jim Simons 318,300 sh (New)
Steven Cohen 1,200 sh (New)
PRIMECAP Management 127,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with XNPT



No Insider Trades Found!

Ratios

vs
industry		 vs
history
P/B 2.00
XNPT's P/B is ranked higher than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. XNPT: 2.00 )
XNPT' s 10-Year P/B Range
Min: 1.71   Max: 13.92
Current: 2
1.71
13.92
P/S 20.70
XNPT's P/S is ranked lower than
60% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. XNPT: 20.70 )
XNPT' s 10-Year P/S Range
Min: 2.65   Max: 111.17
Current: 20.7
2.65
111.17
EV-to-EBIT 31.3
XNPT's EV-to-EBIT is ranked higher than
50% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. XNPT: 31.3 )
XNPT' s 10-Year EV-to-EBIT Range
Min: 50.9   Max: 9027.3
Current: 31.3
50.9
9027.3

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 2.5
XNPT's Price/Net Cash is ranked higher than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. XNPT: 2.5 )
XNPT' s 10-Year Price/Net Cash Range
Min: 2.1   Max: 12.9
Current: 2.5
2.1
12.9
Price/Net Current Asset Value 95.3
XNPT's Price/Net Current Asset Value is ranked higher than
94% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. XNPT: 95.3 )
XNPT' s 10-Year Price/Net Current Asset Value Range
Min: 44.9   Max: 199.6
Current: 95.3
44.9
199.6
Price/Tangible Book 2.1
XNPT's Price/Tangible Book is ranked higher than
70% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. XNPT: 2.1 )
XNPT' s 10-Year Price/Tangible Book Range
Min: 1.8   Max: 11.6
Current: 2.1
1.8
11.6
Price/Median PS Value 1.2
XNPT's Price/Median PS Value is ranked higher than
77% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. XNPT: 1.2 )
XNPT' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 6.5
Current: 1.2
0.2
6.5
Earnings Yield (Greenblatt) 3.20
XNPT's Earnings Yield (Greenblatt) is ranked higher than
67% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. XNPT: 3.20 )
XNPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.3   Max: 3.2
Current: 3.2
1.3
3.2
Forward Rate of Return (Yacktman) -32.72
XNPT's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. XNPT: -32.72 )
XNPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.2   Max: -16.3
Current: -32.72
-22.2
-16.3

Business Description

XenoPort, Inc. was incorporated in the state of Delaware on May 19, 1999. It is a biopharmaceutical company, which is focused on developing and commercializing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. Its innovative product candidates, which it refers to as Transported Prodrugs, are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. The Company intends to focus its development and commercialization efforts on potential treatments of diseases with significant unmet medical needs, with an emphasis on central nervous system, or CNS, disorders. Its product candidate, XP13512 (gabapentin enacarbil), is licensed to Astellas Pharma Inc. in Japan and five Asian countries and to Glaxo Group Limited, or GSK, in the United States and all other regions of the world. Astellas has filed a new drug application, or NDA, with the Pharmaceuticals and Medical Device Agency, or PMDA, for approval of XP13512 as a treatment for restless legs syndrome in Japan. Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. In January 2009, GSK submitted an NDA to the U.S. Food and Drug Administration, or FDA, for U.S. approval to market XP13512, known in the United States by the trade name Horizant (gabapentin enacarbil) Extended-Release Tablets, for the treatment of moderate-to-severe main restless legs syndrome, or RLS. The Company is evaluating its second product candidate, Arbaclofen Placarbil, or AP (previously known as XP19986), for the potential treatment of gastroesophageal reflux disease, or GERD, in patients who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors, or PPIs. It might also evaluate AP as a potential treatment for patients with spasticity. The Company is evaluating its third product candidate, XP21279, for the potential treatment of patients with Parkinson's disease. It holds a composition-of-matter patent and a formulation patent in the United States on XP21279, and hold patents or pending patent applications directed to the XP21279 methods of synthesis and use in the United States. Its fourth product candidate is XP21510, a Transported Prodrug of tranexamic acid, for the potential treatment of menorrhagia, or heavy menstrual bleeding. The Company holds a composition-of-matter patent, formulation patent and method-of-use patent directed to XP21510, and hold patents or pending patent applications directed to the methods of synthesis in the United States. Each of its product candidates is an orally available, patented or patentable new chemical entity that addresses large potential markets. Under the terms of its agreement with GSK, it has co-promotion r
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:LMW.Germany
ยป More Articles for XNPT

Headlines

Articles On GuruFocus.com
XenoPort Inc. Reports Operating Results (10-Q) Nov 09 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2010 
XenoPort Inc. Reports Operating Results (10-Q) May 10 2010 
Xenoport - A Shaking Ham Hock Feb 07 2010 
XenoPort Inc. Reports Operating Results (10-Q) Aug 06 2009 
Weekly Top Insider Buys: Alcoa Inc., ABM Industries Inc., Valhi Inc., XenoPort Inc., and Methode Ele Jul 11 2009 
XenoPort Inc. Reports Operating Results (10-Q) May 07 2009 
Weekly Top Insider Buys: Sovereign Bancorp Inc., Jefferies Group Inc., XenoPort Inc., Sandridge Ener May 24 2008 


Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial